Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O 6 -methylguanine–DNA
methyltransferase promotor, standard temozolomide (TMZ) has, at best, …

Purpose: Pseudoprogression (PsP) is characterized by therapy-associated but not tumor
growth–associated increases of contrast-enhancing glioblastoma lesions on MRI. Although …

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran
that reverses its anticoagulant effects within minutes. It may exhibit the potential for patients …

Smart manufacturing demands to process data in domain-specific real-time. Engineering
models created for constructing, commissioning, planning, or simulating manufacturing …

Purpose: Investigation of clonal heterogeneity may be key to understanding mechanisms of
therapeutic failure in human cancer. However, little is known on the consequences of …

Background Molecularly targeted therapies using receptor inhibitors, small molecules or
monoclonal antibodies are routinely applied in oncology. Verification of target expression …

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran
reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic …

Background This analysis aims at evaluating the impact of multidisciplinary tumor boards on
clinical outcome of multiple tumor entities, the effect of the specific number of …

Purpose In the randomized G-PCNSL-SG-1 trial, the addition of whole brain radiotherapy (45
Gy) to high-dose methotrexate (HD-MTX)-based chemotherapy (early WBRT arm) did not …

In patients with glioblastoma, it is critical to correctly determine the time point of tumor
progression. An incorrect diagnosis of progression (pseudoprogression) implies that a successful …